User profiles for Britton Boras
 | Britton BorasTranslational Modeling and Simulation, Pfizer Verified email at pfizer.com Cited by 2101 |
[HTML][HTML] Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
B Boras, RM Jones, BJ Anson, D Arenson… - Nature …, 2021 - nature.com
COVID-19 caused by the SARS-CoV-2 virus has become a global pandemic. 3CL protease
is a virally encoded protein that is essential across a broad spectrum of coronaviruses with …
is a virally encoded protein that is essential across a broad spectrum of coronaviruses with …
[PDF][PDF] Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor
…, M Xu, JE Solowiej, R Visswanathan, B Boras… - Cancer cell, 2021 - cell.com
The CDK4/6 inhibitor, palbociclib (PAL), significantly improves progression-free survival in
HR + /HER2 − breast cancer when combined with anti-hormonals. We sought to discover PAL …
HR + /HER2 − breast cancer when combined with anti-hormonals. We sought to discover PAL …
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer
…, RL Hoffman, DC Behenna, B Boras… - Journal of Medicinal …, 2021 - ACS Publications
Control of the cell cycle through selective pharmacological inhibition of CDK4/6 has proven
beneficial in the treatment of breast cancer. Extending this level of control to additional cell …
beneficial in the treatment of breast cancer. Extending this level of control to additional cell …
Disposition of nirmatrelvir, an orally bioavailable inhibitor of SARS-CoV-2 3C-like protease, across animals and humans
…, RS Obach, L Di, J Lin, NC Patel, B Boras… - Drug Metabolism and …, 2022 - ASPET
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like protease inhibitor
PF-07321332 (nirmatrelvir), in combination with ritonavir (Paxlovid), was recently granted …
PF-07321332 (nirmatrelvir), in combination with ritonavir (Paxlovid), was recently granted …
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19
The worldwide outbreak of COVID-19 caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, antiviral …
coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, antiviral …
[HTML][HTML] A computational modeling and simulation approach to investigate mechanisms of subcellular cAMP compartmentation
Subcellular compartmentation of the ubiquitous second messenger cAMP has been widely
proposed as a mechanism to explain unique receptor-dependent functional responses. How …
proposed as a mechanism to explain unique receptor-dependent functional responses. How …
Discovery of a novel inhibitor of coronavirus 3CL protease for the potential treatment of COVID-19
B Boras, RM Jones, BJ Anson, D Arenson… - BioRxiv, 2020 - biorxiv.org
COVID-19 caused by the SARS-CoV-2 virus has become a global pandemic. 3CL protease
is a virally encoded protein that is essential to the viral life cycle across a broad spectrum of …
is a virally encoded protein that is essential to the viral life cycle across a broad spectrum of …
[HTML][HTML] Nanoparticles for improved local retention after intra-articular injection into the knee joint
M Morgen, D Tung, B Boras, W Miller, AM Malfait… - Pharmaceutical …, 2013 - Springer
Purpose To evaluate using cationic polymeric nanoparticles that interact with hyaluronate to
form ionically cross-linked hydrogels to increase the intra-articular retention time of …
form ionically cross-linked hydrogels to increase the intra-articular retention time of …
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19
…, BM Bechle, MA Behzadi, B Boras… - Journal of Medicinal …, 2024 - ACS Publications
Despite the record-breaking discovery, development and approval of vaccines and antiviral
therapeutics such as Paxlovid, coronavirus disease 2019 (COVID-19) remained the fourth …
therapeutics such as Paxlovid, coronavirus disease 2019 (COVID-19) remained the fourth …
[HTML][HTML] Using Markov state models to develop a mechanistic understanding of protein kinase A regulatory subunit RIα activation in response to cAMP binding
Protein kinase A (PKA) holoenzyme consists of two catalytic (C) subunits and a regulatory (R)
subunit dimer (R 2 C 2 ). The kinase is activated by the binding of cAMPs to the two cyclic …
subunit dimer (R 2 C 2 ). The kinase is activated by the binding of cAMPs to the two cyclic …